SCHEMBL8075624

SCHEMBL8075624

Cc1cc2ccc(CCl)cc2[nH]c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.54
▸ DAO P14920 3/20 0.50
▸ DDO Q99489 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ HIF1A Q16665 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ GRIN2D O15399 2/20 0.38
▸ GRIN3B O60391 2/20 0.38
▸ GRIN1 Q05586 2/20 0.38
▸ GRIN2A Q12879 2/20 0.38
▸ GRIN2B Q13224 2/20 0.38
▸ GRIN2C Q14957 2/20 0.38
▸ GRIN3A Q8TCU5 2/20 0.38
▸ ATAD2 Q6PL18 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31159560 0.83 BRD4 (0.54) BRD4DAODDOALDH1A1KDM4E
SCHEMBL8073142 0.83 BRD4 (0.54) BRD4DAODDOALDH1A1KDM4E
SCHEMBL25093894 0.82 DAO (0.56) DAOALDH1A1KDM4EHSD17B10HIF1A
SCHEMBL30663247 0.82 DAO (0.56) DAOALDH1A1KDM4EHSD17B10HIF1A
SCHEMBL4388117 0.77 DAO (0.64) BRD4DAODDOALDH1A1GRIN2D
SCHEMBL15478601 0.77 DAO (0.68) BRD4DAODDOALDH1A1KDM4E
SCHEMBL1038770 0.74 BRD4 (0.47) BRD4DAODDOALDH1A1KDM4E
SCHEMBL1038241 0.74 BRD4 (0.59) BRD4DAODDOALDH1A1KDM4E
SCHEMBL1438376 0.74 BRD4 (0.59) BRD4DAODDOALDH1A1KDM4E
SCHEMBL1709827 0.74 BRD4 (0.59) BRD4DAODDOALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404713-B2 Quinolinone derivatives as PARP inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-03-26 — — US disclosed
US-8404713-B2 Quinolinone derivatives as PARP inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-03-26 — — US disclosed
US-20100222348-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-09-02 — — US disclosed
US-20100222348-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-09-02 — — US disclosed
WO-2009053373-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222348-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS PARP1, PARP2, PARP11 BRD4 211/4885DAO 3543/4885DDO 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback